Therapeutic angiogenesis shows promise but questions remain Newsletter Article 06 February 2013 Pages: 2 - 2
Recommendations for the use of antithrombotics in children Newsletter Article 06 February 2013 Pages: 3 - 3
Guidelines for treating CMV diseases in patients with AIDS Newsletter Article 06 February 2013 Pages: 4 - 4
Terbinafine superior to itraconazole in onychomycosis Newsletter Article 06 February 2013 Pages: 5 - 5
Paclitaxel prepares for first-line in advanced ovarian cancer Mark Greener Newsletter Article 06 February 2013 Pages: 6 - 7
Cost analysis of protease inhibitor therapy in HIV infection in Canada Newsletter Article 06 February 2013 Pages: 7 - 7
Imperfect HIV vaccines could still be cost effective Newsletter Article 06 February 2013 Pages: 7 - 7
Delayed surfactant administration an option in premature neonates Newsletter Article 06 February 2013 Pages: 8 - 8
Expanding horizons for endothelin-receptor antagonists Wayne Elwood Newsletter Article 06 February 2013 Pages: 9 - 10
IgG avidity for polysaccharides distinguishes vaccines Newsletter Article 06 February 2013 Pages: 10 - 10
MPI-5010 may help in the treatment of solid tumours Newsletter Article 06 February 2013 Pages: 11 - 11
Radiotherapy + chemotherapy effective in head and neck cancer Newsletter Article 06 February 2013 Pages: 12 - 12
Angiotensin II antagonists lead the way in hypertension management Martin Gallagher Newsletter Article 06 February 2013 Pages: 13 - 14
Conservative approach favoured in acute non-Q-wave MI Newsletter Article 06 February 2013 Pages: 15 - 15
A closer look at reduction in hip fracture risk with HRT Newsletter Article 06 February 2013 Pages: 17 - 17
Miglitol effective in elderly patients with type 2 diabetes Newsletter Article 06 February 2013 Pages: 18 - 18
A different explanation for the efficacy of macrolides in CHD? Newsletter Article 06 February 2013 Pages: 20 - 20
Mibefradil - an example of ‘overprecipitous approval’? Newsletter Article 06 February 2013 Pages: 21 - 21
